MedTrace Logo

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

NCT04390178 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-12-16

No results posted yet for this study

Summary

There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness.

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 convalescent plasma

Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection

Sponsors & Collaborators

  • Danderyd Hospital

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Joakim Dillner

    lead OTHER

Principal Investigators

  • Johan Ursing, MD, PhD · Danderyd Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390178 on ClinicalTrials.gov